Dashboard
Manage Tickers

TSX:AEZSna


na (na)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.83 $ 0.25 (0.05 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.23 (0.04 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ na
-- x --
-- x --
-- - --
na - na
0
na
na
na
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Aeterna Zentaris Inc. Announces Name Chang...
08/06/2024 22:10:20

COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ:AEZS) (TSX:AEZS) ("COSCIENS" or the "Company")...

Core News & Articles
Aeterna Zentaris Set To Regain Full Rights...
08/29/2022 12:06:15

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializ...

Core News & Articles
Aeterna Zentaris Announces Shareholder App...
07/15/2022 20:17:05

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical comp...

Core News & Articles
Aeterna Zentaris' Licensing Partner, Consi...
05/25/2022 12:08:37

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing a...

Core News & Articles
Aeterna Zentaris Provides Update On Pre-Cl...
05/12/2022 12:18:37

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical comp...

Core News & Articles
Aeterna Zentaris Abstract Accepted For Pre...
04/25/2022 12:10:43

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical comp...

Core News & Articles
Aeterna Zentaris Reports Secured New Europ...
04/19/2022 12:07:29

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as th...

Core News & Articles
Aeterna Zentaris Provides Update On Ongoin...
03/21/2022 12:08:24

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical comp...

Core News & Articles
Aeterna Zentaris Reports Expansion Of The ...
03/10/2022 12:26:38

– Research agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis T...

Core News & Articles
Aeterna Zentaris Granted 180-Day Extension...
01/26/2022 21:40:08

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical comp...

Core News & Articles
Aeterna Zentaris Provides Business Outlook...
01/26/2022 13:18:03

– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial pos...

Core News & Articles
Aeterna Zentaris Receives Nasdaq Notificat...
07/29/2021 12:20:27

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing a...

Core News & Articles
Aeterna Zentaris Announces Start Of Precli...
05/17/2021 12:11:51

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the "Company" or "Aeterna Zentaris"), a specialty biopharmaceut...

Core News & Articles
Aeterna Zentaris Reports Commencement Of P...
05/13/2021 12:05:56

– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA")...

Core News & Articles
Aeterna Zentaris Reports Regained Nasdaq C...
03/22/2021 20:07:03

Core News & Articles
Aeterna Zentaris Announces Exclusive Licen...
03/15/2021 12:18:52

- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclus...

Core News & Articles
Aeterna Zentaris Initiates Preclinical Pro...
03/11/2021 13:15:42

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid ho...

Core News & Articles
Aeterna Zentaris Shares See Volume; Co Ann...
02/19/2021 18:26:46

Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares CHARLESTON, S.C., Feb. 19, 2021 (GLO...

Core News & Articles
Aeterna Zentaris Increases Previously Anno...
02/17/2021 10:54:52

Aeterna Zentaris Inc.

Core News & Articles
Aeterna Zentaris Reports Evaluation, Poten...
02/02/2021 12:30:55

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “C...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION